The interleukin (IL-4) and IL-13 inhibitor dupilumab is an effective treatment for patients with severe chronic rhinosinusitis with nasal polyps, two new studies show.

The results of the trials — one which ran for six months and one for a year — showed that patients on fortnightly dupilumab subcutaneous injections had a greater reduction in nasal polyp size than those on placebo.

The pharma-funded studies involved 724 patients across 25 different countries including Australia.

Participants (mean age 52, 40% female) had severe disease, with an average duration of 11 years.